EGFRvⅢ-targeted immunotoxin combined with temozolomide and bispecific antibody for the eradication of established glioblastoma

EGFRvⅢ-targeted immunotoxin combined with temozolomide and bispecific antibody for the eradication of established glioblastoma

EGFRvⅢ is an established target for immunotherapy of glioblastoma (GBM). Current study aims to explore the efficacy of EGFRvⅢ-targeted immunotoxin combined with temozolomide (TMZ) or T cell-engaged bispecific antibody for the treatment of GBM. We generated three rabbit monoclonal antibodies (R1, R2,...

Full description

Bibliographic Details
Main Authors: Le Huang, Huixia He, Ke Wang, Xuqian Ma, Xin Chen, Wenxin Chen, Xuan Wang, Xiaobing Jiang, Mingqian Feng
Format: Article
Language:English
Published: Elsevier 2022-11-01
Series:Biomedicine & Pharmacotherapy
Subjects:
EGFRvⅢ
Glioblastoma
Temozolomide
Immunotoxin
Bispecific antibody
Online Access:http://www.sciencedirect.com/science/article/pii/S0753332222010484

Internet

http://www.sciencedirect.com/science/article/pii/S0753332222010484

Similar Items